<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159198</url>
  </required_header>
  <id_info>
    <org_study_id>CRC01107</org_study_id>
    <secondary_id>P011023</secondary_id>
    <nct_id>NCT00159198</nct_id>
    <nct_alias>NCT00140777</nct_alias>
  </id_info>
  <brief_title>Amyotrophic Lateral Sclerosis and Frontotemporal Dementia</brief_title>
  <official_title>Genetic Linkage in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) is a rare clinical
      entity, in which both disorders are variably associated in the same patient or within the
      family. This adult-onset disorder, which is rapidly fatal, occurs in some families with
      autosomal dominant (AD) transmission and age-dependant penetrance. Two studies have provided
      evidence for linkage of this condition to chromosomes 15 (in a single family) and 9 (in five
      families). However, none of these loci have been yet confirmed. Through a national network of
      10 centres with specialists for FTD and/or ALS, we have identified 35 probands with ALS-FTD,
      including 13 with a family history consistent with AD inheritance.

      Mutations in the SOD1 and tau genes, respectively responsible for autosomal dominant forms of
      ALS and FTD, will be excluded by direct sequencing. We will then extend the pedigree of the
      13 autosomal dominant families to all consenting first, second and eventually third degree
      relatives, using well defined criteria for FTD and ALS. The same strategy will be applied to
      newly identified families during the course of the project (at least, seven families with AD
      inheritance expected). Linkage studies will be performed in the 20 families using markers
      from the two candidate regions on chromosomes 9 and 15. Then, refinement of the candidate
      region will be obtained by analyzing the linked families with a high density of
      microsatellite markers. This should lead to the refinement of the candidate regions, allowing
      to search for mutations in candidate genes. Genes located within the critical regions will be
      prioritized for their analysis by sequencing, according to their expression in the nervous
      system and to their function.

      Once the responsible gene(s) will be identified, it will then possible to define its spectrum
      of mutations and to establish genotype/phenotype correlations. Alternatively, if none of the
      candidate regions is confirmed, a genome wide search will be performed, allowing to identify
      one or more loci for ALS-FTD. The same strategy would then be applied to identify the
      corresponding gene(s). This project should contribute for identifying the molecular basis of
      this devastating disorder with practical consequences for genetic counselling in ALS-FTD
      families, and with the perspective of elucidating the pathophysiology of this disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study without direct individual benefit is to confirm the linkage with
      one or another region of the two identified regions (chromosomes 9 and 15) or to identify a
      new implicated chromosomal region, and then to reduce the linkage interval in order to
      identify the responsible gene(s) and characterize the mutations with the study of at least 9
      families with FTD and ALS.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Completed
  </why_stopped>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with frontotemporal dementia and amyotrophic lateral sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Relatives (first and second degree) of patients presenting an association of frontotemporal dementia with amyotrophic lateral sclerosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients and relatives coming in outcome clinics. They are all volunteers and agree to give
        a blood sample and signing an informed consent explaining the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALS with FTD, &quot;pure&quot; FTD but with knowledge of relatives with ALS-FTD or &quot;pure&quot; ALS,
             &quot;pure&quot; ALS but with knowledge of relatives with ALS-FTD or &quot;pure&quot; FTD (not carriers of
             a mutation in the tau and SOD1 genes), relatives signing the informed consent

        Exclusion Criteria:

          -  Minors, persons refusing to sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexis Brice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris, University Paris 6</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de la Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte-Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Guillaume et René Laënnec</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière - Centre du Langage-Neuropsychologie</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière - Fédération de Neurologie</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bellevue</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.aphp.fr</url>
  </link>
  <results_reference>
    <citation>Le Ber I, Guedj E, Gabelle A, Verpillat P, Volteau M, Thomas-Anterion C, Decousus M, Hannequin D, Véra P, Lacomblez L, Camuzat A, Didic M, Puel M, Lotterie JA, Golfier V, Bernard AM, Vercelletto M, Magne C, Sellal F, Namer I, Michel BF, Pasquier J, Salachas F, Bochet J; French research network on FTD/FTD-MND, Brice A, Habert MO, Dubois B. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain. 2006 Nov;129(Pt 11):3051-65.</citation>
    <PMID>17071924</PMID>
  </results_reference>
  <results_reference>
    <citation>van der Zee J, Le Ber I, Maurer-Stroh S, Engelborghs S, Gijselinck I, Camuzat A, Brouwers N, Vandenberghe R, Sleegers K, Hannequin D, Dermaut B, Schymkowitz J, Campion D, Santens P, Martin JJ, Lacomblez L, De Pooter T, Peeters K, Mattheijssens M, Vercelletto M, Van den Broeck M, Cruts M, De Deyn PP, Rousseau F, Brice A, Van Broeckhoven C. Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat. 2007 Apr;28(4):416.</citation>
    <PMID>17345602</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, Puel M, Laquerrière A, De Pooter T, Camuzat A, Van den Broeck M, Dubois B, Sellal F, Lacomblez L, Vercelletto M, Thomas-Antérion C, Michel BF, Golfier V, Didic M, Salachas F, Duyckaerts C, Cruts M, Verpillat P, Van Broeckhoven C, Brice A; French Research Network on FTD/FTD-MND. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat. 2007 Sep;28(9):846-55.</citation>
    <PMID>17436289</PMID>
  </results_reference>
  <results_reference>
    <citation>Guedj E, Le Ber I, Lacomblez L, Dubois B, Verpillat P, Didic M, Salachas F, Vera P, Hannequin D, Lotterie JA, Puel M, Decousus M, Thomas-Antérion C, Magne C, Vercelletto M, Bernard AM, Golfier V, Pasquier J, Michel BF, Namer I, Sellal F, Bochet J, Volteau M, Brice A, Meininger V; French Research Network on FTD/FTD-MND, Habert MO. Brain spect perfusion of frontotemporal dementia associated with motor neuron disease. Neurology. 2007 Jul 31;69(5):488-90.</citation>
    <PMID>17664410</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A, Hahn-Barma V, van der Zee J, Clot F, Bakchine S, Puel M, Ghanim M, Lacomblez L, Mikol J, Deramecourt V, Lejeune P, de la Sayette V, Belliard S, Vercelletto M, Meyrignac C, Van Broeckhoven C, Lambert JC, Verpillat P, Campion D, Habert MO, Dubois B, Brice A; French research network on FTD/FTD-MND. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain. 2008 Mar;131(Pt 3):732-46. doi: 10.1093/brain/awn012. Epub 2008 Feb 1.</citation>
    <PMID>18245784</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 5, 2008</last_update_submitted>
  <last_update_submitted_qc>September 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Isabelle BRINDEL</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>Amyotrophic lateral sclerosis</keyword>
  <keyword>Frontotemporal dementia</keyword>
  <keyword>Mutations spectrum</keyword>
  <keyword>Linkage studies</keyword>
  <keyword>Genetic epidemiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

